GBS vs AMAN vs AMSAN: Electrophysiological Subtypes
GBS is an umbrella term encompassing three main electrophysiological subtypes: AIDP (acute inflammatory demyelinating polyradiculoneuropathy), AMAN (acute motor axonal neuropathy), and AMSAN (acute motor-sensory axonal neuropathy), which differ fundamentally in their pathophysiology, clinical presentation, and prognosis. 1
Key Distinguishing Features
Pathophysiology
- AIDP: Demyelinating process affecting myelin sheath and Schwann cells
- AMAN: Pure axonal degeneration affecting motor nerves only, often with reversible conduction failure (RCF)
- AMSAN: Axonal degeneration affecting both motor and sensory nerves 2, 3
Clinical Presentation
AIDP (Classic GBS)
- Sensorimotor involvement with distal paresthesias
- Ascending weakness from legs to arms and cranial muscles
- Areflexia or hyporeflexia (decreased/absent reflexes)
- Dysautonomia common
- CSF shows albuminocytologic dissociation in 71.7% 4
AMAN
- Pure motor weakness without sensory symptoms
- May present with normal or even exaggerated reflexes (critical distinguishing feature) 1
- Lower MRC scores (30.1 vs 36.4 in AIDP) 4
- Less frequent facial palsy (10% vs 25.9%) 4
- Lower rate of CSF protein elevation (41.3% vs 71.7%) 4
- Can show reversible conduction failure mimicking demyelination 2, 5
AMSAN
- Combined motor and sensory axonal involvement
- Most severe presentation
- Sensory loss accompanies motor weakness
- Higher mortality risk 6
Electrophysiological Differentiation
Critical diagnostic approach: Serial nerve conduction studies are mandatory, as initial studies may be equivocal in one-third of patients 1. Repeat testing at 3-8 weeks improves classification accuracy 1, 2.
AIDP findings:
- Demyelinating features: prolonged distal latencies, conduction slowing, temporal dispersion
- Conduction blocks with temporal dispersion
AMAN findings:
- Reduced compound muscle action potential (CMAP) amplitudes
- Normal or near-normal conduction velocities
- Reversible conduction failure (RCF) pattern without temporal dispersion 2, 5
- Longer relative refractory period (4.40 vs 3.09 ms) 7
- Less prominent superexcitability (-6.80% vs -26.48%) 7
AMSAN findings:
- Reduced motor and sensory nerve action potential amplitudes
- Axonal degeneration pattern on serial studies 5
Prognostic Implications
AMAN is an independent predictor of poor outcome (OR 3.34, p=0.03), with inability to walk independently at 3 months more likely than AIDP 4. However, this depends on whether RCF or true axonal degeneration is present:
- AMAN with RCF: Better prognosis, less severe evolution (GBSds ≤1 at 12 months) 5
- AMAN/AMSAN with axonal degeneration: Worse prognosis (GBSds ≥2 at 12 months), higher morbidity and mortality 6, 5
AMSAN has the highest mortality risk among subtypes, with 8.3% mortality in pediatric series 6. Axonal forms show more severe evolution than demyelinating forms at 3 months (median GBSds 3 vs 2), 6 months (2 vs 0), and 12 months (1 vs 0) 5.
Critical Pitfalls to Avoid
Don't misclassify AMAN as AIDP: RCF in AMAN can mimic demyelinating conduction block, but lacks temporal dispersion 2. This distinction requires serial studies.
Don't assume all axonal GBS has poor prognosis: RCF pattern indicates potential for good recovery 5
Don't rely on single electrophysiological study: About one-third of patients are initially "equivocal" or "inexcitable" 1
Don't expect typical areflexia in AMAN: Normal or exaggerated reflexes may persist throughout disease course 1
Don't wait for CSF abnormalities: Protein elevation occurs in only 41.3% of AMAN cases vs 71.7% in AIDP 4
Treatment Considerations
All subtypes receive identical immunotherapy: IVIg 0.4 g/kg daily for 5 days or plasma exchange 200-250 ml/kg for 5 sessions 1, 8. The subtype classification primarily informs prognosis rather than treatment selection, though axonal forms may require more aggressive supportive care and longer rehabilitation 6, 5.